Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. UK virus hunting labs seek to bolster global variant network 2 hours ago.
Related Stories. Dec 14, Nov 29, Nov 24, Jul 30, Recommended for you. New cloud-based platform opens genomics data to all 15 hours ago. Load comments 0. Let us know if there is a problem with our content. Your message to the editors. Your email only if you want to be contacted back. Send Feedback.
Thank you for taking time to provide your feedback to the editors. Your friend's email. Your email. I would like to subscribe to Science X Newsletter. Learn more. Your name. Note Your email address is used only to let the recipient know who sent the email.
Your message. Your Privacy This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. A Variant of Interest might require one or more appropriate public health actions, including enhanced sequence surveillance, enhanced laboratory characterization, or epidemiological investigations to assess how easily the virus spreads to others, the severity of disease, the efficacy of therapeutics and whether currently approved or authorized vaccines offer protection.
A variant for which there is evidence of an increase in transmissibility, more severe disease for example, increased hospitalizations or deaths , significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures.
Variants of concern might require one or more appropriate public health actions, such as notification to WHO under the International Health Regulations, reporting to CDC, local or regional efforts to control spread, increased testing, or research to determine the effectiveness of vaccines and treatments against the variant.
Based on the characteristics of the variant, additional considerations may include the development of new diagnostics or the modification of vaccines or treatments. Current variants of concern in the United States that are being closely monitored and characterized are listed below. This table will be updated when a new variant of concern is identified. The goal is to support public health surveillance by facilitating understanding of the spread and evolution of pathogens.
WHO Label : Delta. Pango Lineage: B. Nextstrain clade Nextstrain external icon b : 21K. A VOHC has clear evidence that prevention measures or medical countermeasures MCMs have significantly reduced effectiveness relative to previously circulating variants.
A variant of high consequence would require notification to WHO under the International Health Regulations, reporting to CDC, an announcement of strategies to prevent or contain transmission, and recommendations to update treatments and vaccines. Sequences with similar genetic changes are grouped into lineages, and multiple lineages can have the same substitutions.
For example, the EK substitution is found in lineages B. Genomic surveillance efforts provide the capability to detect viruses that have reduced susceptibility to treatments more quickly. Reduced susceptibility of SARS-CoV-2 to sotrovimab external icon or the combination of casirivimab and imdevimab external icon has not been reported.
In laboratory studies, SARS-CoV-2 variants that contain certain substitutions in the spike protein have reduced susceptibility to the combination of bamlanivimab and etesevimab external icon. Given the predominance of the Delta variant in the United States, it is important to note that the vast majority of Delta variant lineages are sensitive to the combination of bamlanivimab and etesevimab.
Although Delta variants contain the LR substitution, the combination of the LR and TK substitutions found in most Delta variants results in no change in the susceptibility to the combination of bamlanivimab and etesevimab, as noted in the FDA Fact Sheet for Health Care Providers external icon.
The proportion data below show the national and regional unweighted proportions of SARS-CoV-2 that contain the following individual or combinations of spike protein substitutions that reduce susceptibility to the combination of bamlanivimab and etesevimab that are listed in the FDA Fact Sheet for Health Care Providers for EUA of Bamlanivimab and Etesevimab external icon.
As new data become available, additional substitutions may be added below. The national and regional proportions provided below will be updated weekly. Skip directly to site content Skip directly to page options Skip directly to A-Z link. Section Navigation. Important update: Healthcare facilities. Learn more.
Updated Dec. Minus Related Pages. On This Page. Mutations happen frequently, but only sometimes change the characteristics of the virus. Lineage: A lineage is a group of closely related viruses with a common ancestor. Variant: A variant is a viral genome genetic code that may contain one or more mutations.
In some cases, a group of variants with similar genetic changes, such as a lineage or group of lineages, may be designated by public health organizations as a Variant of Concern VOC or a Variant of Interest VOI due to shared attributes and characteristics that may require public health action.
To receive email updates when a variant classification or definition changes, enter your email address: Email Address. What's this? Possible attributes of a Variant of Interest: Specific genetic markers that are predicted to affect transmission, diagnostics, therapeutics, or immune escape. Evidence that it is the cause of an increased proportion of cases or unique outbreak clusters. Limited prevalence or expansion in the US or in other countries. Variant of Concern VOC A variant for which there is evidence of an increase in transmissibility, more severe disease for example, increased hospitalizations or deaths , significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures.
Possible attributes of a variant of concern: In addition to the possible attributes of a variant of interest Evidence of impact on diagnostics, treatments, or vaccines Widespread interference with diagnostic test targets Evidence of substantially decreased susceptibility to one or more class of therapies Evidence of significantly decreased neutralization by antibodies generated during previous infection or vaccination Evidence of reduced vaccine-induced protection from severe disease Evidence of increased transmissibility Evidence of increased disease severity Variants of concern might require one or more appropriate public health actions, such as notification to WHO under the International Health Regulations, reporting to CDC, local or regional efforts to control spread, increased testing, or research to determine the effectiveness of vaccines and treatments against the variant.
Footnotes for Variants of Concern. Regional Proportions b Region 1.
0コメント